Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have received an average rating of “Moderate Buy” from the fourteen research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $42.40.

A number of research analysts have weighed in on the company. Guggenheim decreased their price target on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Citigroup cut their price objective on Olema Pharmaceuticals to $59.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. JPMorgan Chase & Co. decreased their target price on shares of Olema Pharmaceuticals from $52.00 to $46.00 and set an “overweight” rating for the company in a research note on Thursday, August 13th. HC Wainwright lowered their target price on shares of Olema Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Finally, Wall Street Zen lowered shares of Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 25th.

Insider Buying and Selling at Olema Pharmaceuticals

In other news, Director Cyrus Harmon sold 12,500 shares of the business’s stock in a transaction dated Thursday, July 23rd. The shares were sold at an average price of $11.58, for a total transaction of $144,750.00. Following the transaction, the director directly owned 715,270 shares in the company, valued at $8,282,826.60. The trade was a 1.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 12.56% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Olema Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of OLMA. Siren L.L.C. raised its stake in Olema Pharmaceuticals by 44.1% in the first quarter. Siren L.L.C. now owns 4,756,949 shares of the company’s stock valued at $70,926,000 after buying an additional 1,456,249 shares during the period. Jennison Associates LLC bought a new position in shares of Olema Pharmaceuticals during the 4th quarter worth approximately $24,100,000. SEB Asset Management AB bought a new position in shares of Olema Pharmaceuticals during the 1st quarter worth approximately $5,061,000. Defilade Capital Management L.P. increased its holdings in shares of Olema Pharmaceuticals by 21.9% during the 1st quarter. Defilade Capital Management L.P. now owns 1,504,536 shares of the company’s stock worth $22,433,000 after acquiring an additional 269,902 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Olema Pharmaceuticals by 12.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,082,434 shares of the company’s stock worth $16,134,000 after acquiring an additional 123,790 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Trading Down 2.4%

Olema Pharmaceuticals stock opened at $10.43 on Tuesday. The company has a market cap of $912.62 million, a price-to-earnings ratio of -4.92 and a beta of 2.03. The firm has a 50-day moving average of $11.35 and a 200-day moving average of $14.71. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.86 and a quick ratio of 8.86. Olema Pharmaceuticals has a one year low of $5.36 and a one year high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Monday, August 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.06). On average, equities analysts expect that Olema Pharmaceuticals will post -2.43 earnings per share for the current fiscal year.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.